{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:43:45Z","timestamp":1790642625798,"version":"4.1.0"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. National Institutes of Health","doi-asserted-by":"crossref","award":["CA135274"],"award-info":[{"award-number":["CA135274"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"U.S. National Institutes of Health","doi-asserted-by":"crossref","award":["CA179362"],"award-info":[{"award-number":["CA179362"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81460454"],"award-info":[{"award-number":["81460454"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Inner Mongolia Natural Science Fund","award":["2014ZD05"],"award-info":[{"award-number":["2014ZD05"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ejpb.2017.11.001","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T16:00:13Z","timestamp":1509984013000},"page":"167-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Intranasal immunization with dry powder vaccines"],"prefix":"10.1016","volume":"122","author":[{"given":"Tania F.","family":"Bahamondez-Canas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengrong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2017.11.001_b0005","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.resp.2008.05.002","article-title":"Air-conditioning in the human nasal cavity","volume":"163","author":"Elad","year":"2008","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.ejpb.2017.11.001_b0010","series-title":"CT of the Airways","author":"Boiselle","year":"2008"},{"key":"10.1016\/j.ejpb.2017.11.001_b0015","doi-asserted-by":"crossref","unstructured":"O.E. Ogle, R.J. Weinstock, E. Friedman, Surgical anatomy of the nasal cavity and paranasal sinuses, Oral Maxillofac Surg Clin North Am, 24 (2012) pp. 155\u2013166, vii.","DOI":"10.1016\/j.coms.2012.01.011"},{"key":"10.1016\/j.ejpb.2017.11.001_b0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0169-409X(97)00067-7","article-title":"Nasal delivery systems and their effect on deposition and absorption","volume":"29","author":"Kublik","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2017.11.001_b0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0169-409X(01)00172-7","article-title":"The nose and paranasal sinuses physiology and anatomy","volume":"51","author":"Jones","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2017.11.001_b0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1128\/CDLI.7.1.31-39.2000","article-title":"Immunoglobulins in nasal secretions of healthy humans: structural integrity of secretory immunoglobulin A1 (IgA1) and occurrence of neutralizing antibodies to IgA1 proteases of nasal bacteria","volume":"7","author":"Kirkeby","year":"2000","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.ejpb.2017.11.001_b0035","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1183\/09031936.03.00072003","article-title":"Biological markers in nasal secretions","volume":"21","author":"Riechelmann","year":"2003","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejpb.2017.11.001_b0040","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1128\/IAI.67.7.3267-3275.1999","article-title":"Innate antimicrobial activity of nasal secretions","volume":"67","author":"Cole","year":"1999","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejpb.2017.11.001_b0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0385-8146(99)00038-3","article-title":"Inflammatory cells in nasal mucosa and nasal polyps","volume":"27","author":"Morinaka","year":"2000","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.ejpb.2017.11.001_b0050","first-page":"125","article-title":"Immunocompetent cells in human nasal polyps and normal mucosa","volume":"31","author":"Linder","year":"1993","journal-title":"Rhinology"},{"key":"10.1016\/j.ejpb.2017.11.001_b0055","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/01926230600865531","article-title":"Normal structure, function, and histology of mucosa-associated lymphoid tissue","volume":"34","author":"Cesta","year":"2006","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejpb.2017.11.001_b0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/mi.2007.9","article-title":"Terminology: nomenclature of mucosa-associated lymphoid tissue","volume":"1","author":"Brandtzaeg","year":"2008","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.ejpb.2017.11.001_b0065","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1055\/s-0030-1255509","article-title":"Lymphatic tissue of the nose (NALT) and larynx (LALT) in species comparison: human, rat, mouse","volume":"64","author":"Pabst","year":"2010","journal-title":"Pneumologie"},{"key":"10.1016\/j.ejpb.2017.11.001_b0070","first-page":"237","article-title":"The Waldeyer's ring","volume":"54","author":"Hellings","year":"2000","journal-title":"Acta Otorhinolaryngol. Belg."},{"key":"10.1016\/j.ejpb.2017.11.001_b0075","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2249.2003.02311.x","article-title":"Nasal-associated lymphoid tissue (NALT): frequency and localization in young children","volume":"134","author":"Debertin","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejpb.2017.11.001_b0080","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1016\/j.vaccine.2015.07.022","article-title":"Mucosal vaccination by the intranasal route. Nose-associated lymphoid tissue (NALT)-Structure, function and species differences","volume":"33","author":"Pabst","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2017.11.001_b0085","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0167-5699(92)90158-4","article-title":"The role of nasopharyngeal lymphoid tissue","volume":"13","author":"Kuper","year":"1992","journal-title":"Immunol. Today"},{"key":"10.1016\/j.ejpb.2017.11.001_b0090","series-title":"Kuby Immunology","author":"Goldsby","year":"2000"},{"key":"10.1016\/j.ejpb.2017.11.001_b0095","doi-asserted-by":"crossref","DOI":"10.1038\/nm1213","article-title":"Mucosal immunity and vaccines","author":"Holmgren","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejpb.2017.11.001_b0100","doi-asserted-by":"crossref","first-page":"7481","DOI":"10.1128\/IAI.69.12.7481-7486.2001","article-title":"Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans","volume":"69","author":"Johansson","year":"2001","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejpb.2017.11.001_b0105","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.vaccine.2003.09.002","article-title":"Comparison of different routes of vaccination for eliciting antibody responses in the human stomach","volume":"22","author":"Johansson","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2017.11.001_b0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0169-409X(01)00149-1","article-title":"Exploiting M cells for drug and vaccine delivery","volume":"50","author":"Clark","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2017.11.001_b0115","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s004289900177","article-title":"Evidence of M cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans","volume":"436","author":"Fujimura","year":"2000","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ejpb.2017.11.001_b0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00428-003-0898-8","article-title":"The role of M cells of human nasopharyngeal lymphoid tissue in influenza virus sampling","volume":"444","author":"Fujimura","year":"2004","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ejpb.2017.11.001_b0125","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nri1777","article-title":"Mucosal vaccines: the promise and the challenge","volume":"6","author":"Neutra","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejpb.2017.11.001_b0130","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1600-065X.1999.tb01339.x","article-title":"Mucosal immunity and tolerance: relevance to vaccine development","volume":"170","author":"Czerkinsky","year":"1999","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejpb.2017.11.001_b0135","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1208\/pt0804081","article-title":"Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination","volume":"8","author":"Garmise","year":"2007","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2017.11.001_b0140","article-title":"Dry powder nasal vaccines as an alternative to needle-based delivery","volume":"26","author":"Garmise","year":"2009","journal-title":"Crit. Rev.\u2122 Therapeutic Drug Carrier Syst."},{"key":"10.1016\/j.ejpb.2017.11.001_b0145","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1016\/j.vaccine.2011.05.027","article-title":"Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine","volume":"29","author":"Velasquez","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2017.11.001_b0150","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2174\/187221110791185015","article-title":"Mucosal delivery of vaccines: role of mucoadhesive\/biodegradable polymers","volume":"4","author":"Garg","year":"2010","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"10.1016\/j.ejpb.2017.11.001_b0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0169-409X(01)00171-5","article-title":"Chitosan as a novel nasal delivery system for vaccines","volume":"51","author":"Illum","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2017.11.001_b0160","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/7385","article-title":"Oral gene delivery with chitosan\u2013DNA nanoparticles generates immunologic protection in a murine model of peanut allergy","volume":"5","author":"Roy","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejpb.2017.11.001_b0165","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0264-410X(00)00309-1","article-title":"A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM 197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery","volume":"19","author":"McNeela","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2017.11.001_b0170","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0378-5173(99)00030-7","article-title":"Effect of chitosan on epithelial permeability and structure","volume":"182","author":"Dodane","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.11.001_b0175","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/jmv.21415","article-title":"Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally","volume":"81","author":"Ghendon","year":"2009","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejpb.2017.11.001_b0180","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/10717544.2014.908427","article-title":"Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: enhancement of mucosal and systemic immune response","volume":"23","author":"Pawar","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2017.11.001_b0185","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.vaccine.2003.11.011","article-title":"Glycol chitosan improves the efficacy of intranasally administrated replication defective human adenovirus type 5 expressing glycoprotein D of bovine herpesvirus 1","volume":"22","author":"Gogev","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2017.11.001_b0190","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1461-5347(98)00099-6","article-title":"Dry powder formulations for pulmonary delivery","volume":"1","author":"Malcolmson","year":"1998","journal-title":"Pharm. Sci. Technol. Today"},{"key":"10.1016\/j.ejpb.2017.11.001_b0195","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S2213-2600(13)70072-9","article-title":"Pulmonary drug delivery: from generating aerosols to overcoming biological barriers\u2014therapeutic possibilities and technological challenges","volume":"1","author":"Ruge","year":"2013","journal-title":"Lancet Respiratory Med."},{"key":"10.1016\/j.ejpb.2017.11.001_b0200","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1513\/pats.200409-049TA","article-title":"The lungs as a portal of entry for systemic drug delivery","volume":"1","author":"Patton","year":"2004","journal-title":"Proc. Am. Thoracic Soc."},{"key":"10.1016\/j.ejpb.2017.11.001_b0205","doi-asserted-by":"crossref","first-page":"8707","DOI":"10.1016\/j.vaccine.2007.10.035","article-title":"Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB\/c mice","volume":"25","author":"Amorij","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2017.11.001_b0210","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2010.02.025","article-title":"A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation","volume":"144","author":"Saluja","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2017.11.001_b0215","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1073\/pnas.0800043105","article-title":"Immunization by a bacterial aerosol","volume":"105","author":"Garcia-Contreras","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejpb.2017.11.001_b0220","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.vaccine.2006.10.019","article-title":"Measles vaccination of macaques by dry powder inhalation","volume":"25","author":"de Swart","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2017.11.001_b0225","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1208\/s12248-010-9192-2","article-title":"Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route","volume":"12","author":"Muttil","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2017.11.001_b0230","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1208\/s12248-010-9193-1","article-title":"Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity","volume":"12","author":"Lu","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2017.11.001_b0235","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1016\/j.vaccine.2014.09.071","article-title":"Safety and immunogenicity of dry powder measles vaccine administered by inhalation: a randomized controlled Phase I clinical trial","volume":"32","author":"Agarkhedkar","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2017.11.001_b0240","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2125.2003.01893.x","article-title":"Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2017.11.001_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.12.040","article-title":"Influence of particle size on regional lung deposition\u2013what evidence is there?","volume":"406","author":"Carvalho","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.11.001_b0250","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.addr.2006.07.010","article-title":"Particle engineering techniques for inhaled biopharmaceuticals","volume":"58","author":"Shoyele","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2017.11.001_b0255","first-page":"340","article-title":"Technology evaluation: FluMist, University of Michigan","volume":"2","author":"Billich","year":"2000","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.ejpb.2017.11.001_b0260","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4161\/hv.22317","article-title":"A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac ((R))) in India","volume":"9","author":"Kulkarni","year":"2013","journal-title":"Hum Vaccin Immunother."},{"key":"10.1016\/j.ejpb.2017.11.001_b0265","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland","volume":"350","author":"Mutsch","year":"2004","journal-title":"New England J. Med."},{"key":"10.1016\/j.ejpb.2017.11.001_b0270","article-title":"Live attenuated and inactivated viral vaccine formulation and nasal delivery: Potential and challenges","author":"Tlaxca","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2017.11.001_b0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CVI.00280-12","article-title":"An adenovirus-vectored nasal vaccine confers rapid and sustained protection against anthrax in a single-dose regimen","volume":"20","author":"Zhang","year":"2013","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.ejpb.2017.11.001_b0280","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1128\/IAI.00581-08","article-title":"A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague","volume":"76","author":"Yamanaka","year":"2008","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejpb.2017.11.001_b0285","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3233\/HAB-1999-9302","article-title":"Measles IgA in the nasal washings of adult volunteers and children immunized intranasally with measles vaccine L-16","volume":"9","author":"Liashenko","year":"1999","journal-title":"Hum Antibodies"},{"key":"10.1016\/j.ejpb.2017.11.001_b0290","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1128\/IAI.66.4.1334-1341.1998","article-title":"Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans","volume":"66","author":"Haneberg","year":"1998","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejpb.2017.11.001_b0295","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/S0264-410X(00)00550-8","article-title":"Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers","volume":"19","author":"Larbig","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2017.11.001_b0300","unstructured":"S.C. Derrick, K. Kolibab, A. Yang, S.L. Morris, Intranasal administration of BCG induces superior protection against an aerosol infection with Mycobacterium tuberculosis in mice, Clin. Vaccine Immunol. (2014) CVI pp. 00394\u201300314."},{"key":"10.1016\/j.ejpb.2017.11.001_b0305","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/1529-0131(199908)42:8<1628::AID-ANR10>3.0.CO;2-T","article-title":"Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine","volume":"42","author":"Tarkowski","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejpb.2017.11.001_b0310","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.biologicals.2009.08.013","article-title":"Stability of vaccines \u2013 Bridging from stability data to continuous safety and efficacy throughout shelf life \u2013 an always reliable approach?","volume":"37","author":"Pfleiderer","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.ejpb.2017.11.001_b0315","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2471\/BLT.13.123471","article-title":"Economic benefits of keeping vaccines at ambient temperature during mass vaccination: the case of meningitis A vaccine in Chad","volume":"92","author":"Lydon","year":"2014","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.ejpb.2017.11.001_b0320","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.vaccine.2004.06.049","article-title":"A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats","volume":"23","author":"Huang","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2017.11.001_b0325","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jps.20484","article-title":"Anthrax vaccine powder formulations for nasal mucosal delivery","volume":"95","author":"Jiang","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2017.11.001_b0330","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1016\/j.vaccine.2016.12.009","article-title":"Stability and pre-formulation development of a plant-produced anthrax vaccine candidate","volume":"35","author":"Jones","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2017.11.001_b0335","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/acs.molpharmaceut.6b00072","article-title":"Optimized formulation of a thermostable spray-dried virus-like particle vaccine against human papillomavirus","volume":"13","author":"Saboo","year":"2016","journal-title":"Mol. Pharmaceut."},{"key":"10.1016\/j.ejpb.2017.11.001_b0340","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jps.22742","article-title":"Stable dry powder formulation for nasal delivery of anthrax vaccine","volume":"101","author":"Wang","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2017.11.001_b0345","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0378-5173(02)00359-9","article-title":"The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations","volume":"246","author":"Price","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.11.001_b0350","unstructured":"FDA, Guidance for the industry: Metered Dose inhalers (MDI) and Dry Powder Inhalers (DPI) drug products, in, 1998."},{"key":"10.1016\/j.ejpb.2017.11.001_b0355","unstructured":"L. Tiozzo Fasiolo, M.D. Manniello, E. Tratta, F. Buttini, A. Rossi, F. Sonvico, F. Bortolotti, P. Russo, G. Colombo, Opportunity and challenges of nasal powders: Drug formulation and delivery, Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejpb.2017.11.001_b0360","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2015.02.035","article-title":"A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution","volume":"204","author":"Li","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2017.11.001_b0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2014.08.032","article-title":"Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants","volume":"475","author":"Dehghan","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.11.001_b0370","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1089\/0894268041457183","article-title":"PEG-PLA nanoparticles as carriers for nasal vaccine delivery","volume":"17","author":"Vila","year":"2004","journal-title":"J. Aerosol. Med."},{"key":"10.1016\/j.ejpb.2017.11.001_b0375","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1021\/mp4000053","article-title":"Preventative vaccine-loaded mannosylated chitosan nanoparticles intended for nasal mucosal delivery enhance immune responses and potent tumor immunity","volume":"10","author":"Yao","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2017.11.001_b0380","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.powtec.2016.01.042","article-title":"Carrier-based dry powder formulation for nasal delivery of vaccines utilizing BSA as model drug","volume":"292","author":"Trows","year":"2016","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2017.11.001_b0385","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijpharm.2004.09.002","article-title":"PLA-PEG particles as nasal protein carriers: the influence of the particle size","volume":"292","author":"Vila","year":"2005","journal-title":"Int. J. Pharmaceut."},{"key":"10.1016\/j.ejpb.2017.11.001_b0390","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s10529-006-9086-7","article-title":"Protective immunity in rats by intranasal immunization with Streptococcus mutans glucan-binding protein D encapsulated into chitosan-coated poly (lactic-co-glycolic acid) microspheres","volume":"28","author":"Zhao","year":"2006","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.ejpb.2017.11.001_b0395","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1016\/j.vaccine.2007.03.046","article-title":"The annual impact of seasonal influenza in the US: measuring disease burden and costs","volume":"25","author":"Molinari","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2017.11.001_b0400","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.1208\/pt070119","article-title":"Formulation of a dry powder influenza vaccine for nasal delivery","volume":"7","author":"Garmise","year":"2006","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2017.11.001_b0405","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.vaccine.2008.12.013","article-title":"Spray-dried powders of starch and crosslinked poly (acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine","volume":"27","author":"Coucke","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2017.11.001_b0410","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s12272-013-0043-4","article-title":"Dry-powder form of chitosan nanospheres containing influenza virus and adjuvants for nasal immunization","volume":"36","author":"Dehghan","year":"2013","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.ejpb.2017.11.001_b0415","first-page":"417","article-title":"New and improved vaccines against diphtheria and tetanus","author":"Rappuoli","year":"1997","journal-title":"New Gen. Vaccines"},{"key":"10.1016\/j.ejpb.2017.11.001_b0420","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/infdis\/142.5.716","article-title":"Immunogenic correlation between cross-reacting material (CRM197) produced by a mutant of Corynebacterium diphtheriae and diphtheria toxoid","volume":"142","author":"Porro","year":"1980","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejpb.2017.11.001_b0425","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1128\/IAI.71.2.726-732.2003","article-title":"Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a","volume":"71","author":"Mills","year":"2003","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejpb.2017.11.001_b0430","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.vaccine.2003.09.012","article-title":"Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan","volume":"22","author":"McNeela","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2017.11.001_b0435","first-page":"47","article-title":"Menjugate (Chiron)","volume":"2","author":"Jones","year":"2001","journal-title":"Curr. Opin. Investig. Drugs (London, England: 2000)"},{"key":"10.1016\/j.ejpb.2017.11.001_b0440","doi-asserted-by":"crossref","first-page":"8256","DOI":"10.1128\/IAI.73.12.8256-8265.2005","volume":"73","author":"Huo","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejpb.2017.11.001_b0445","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1056\/NEJMra0804575","article-title":"Norovirus gastroenteritis","volume":"361","author":"Glass","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2017.11.001_b0450","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.1128\/JVI.66.11.6527-6532.1992","article-title":"Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein","volume":"66","author":"Jiang","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.ejpb.2017.11.001_b0455","doi-asserted-by":"crossref","first-page":"9713","DOI":"10.1128\/JVI.75.20.9713-9722.2001","article-title":"Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses","volume":"75","author":"Guerrero","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.ejpb.2017.11.001_b0460","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1086\/657087","article-title":"Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues","volume":"202","author":"El-Kamary","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejpb.2017.11.001_b0465","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.clim.2012.05.006","article-title":"Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers","volume":"144","author":"Ramirez","year":"2012","journal-title":"Clin Immunol."},{"key":"10.1016\/j.ejpb.2017.11.001_b0470","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa1101245","article-title":"Norovirus vaccine against experimental human Norwalk Virus illness","volume":"365","author":"Atmar","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2017.11.001_b0475","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.vaccine.2016.01.064","article-title":"Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation","volume":"34","author":"Springer","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2017.11.001_b0480","doi-asserted-by":"crossref","first-page":"e0177310","DOI":"10.1371\/journal.pone.0177310","article-title":"Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder","volume":"12","author":"Ball","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2017.11.001_b0485","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4161\/hv.3.3.4011","article-title":"Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge","volume":"3","author":"Huang","year":"2007","journal-title":"Hum. Vaccin"},{"key":"10.1016\/j.ejpb.2017.11.001_b0490","doi-asserted-by":"crossref","unstructured":"C. Bode, G. Zhao, F. Steinhagen, T. Kinjo, D.M. Klinman, CpG DNA as a vaccine adjuvant, 2011.","DOI":"10.1586\/erv.10.174"},{"key":"10.1016\/j.ejpb.2017.11.001_b0495","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1086\/426865","article-title":"Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms","volume":"191","author":"Mikszta","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejpb.2017.11.001_b0500","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1016\/j.vaccine.2006.02.024","article-title":"An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits","volume":"24","author":"Wimer-Mackin","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2017.11.001_b0505","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1016\/j.vaccine.2008.07.062","article-title":"A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge","volume":"26","author":"Klas","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2017.11.001_b0510","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejpb.2003.09.006","article-title":"Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice","volume":"57","author":"Vila","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2017.11.001_b0515","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/10611860903434035","article-title":"Preparation and in vivo study of dry powder microspheres for nasal immunization","volume":"18","author":"Tafaghodi","year":"2010","journal-title":"J. Drug Targeting"},{"key":"10.1016\/j.ejpb.2017.11.001_b0520","series-title":"Controlled Pulmonary Drug Delivery","first-page":"203","article-title":"Science and technology of Dry Powder Inhalers","author":"Crowder","year":"2011"},{"key":"10.1016\/j.ejpb.2017.11.001_b0525","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s13346-012-0108-9","article-title":"Nasal drug delivery devices: characteristics and performance in a clinical perspective\u2014a review","volume":"3","author":"Djupesland","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejpb.2017.11.001_b0530","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/head.12472","article-title":"Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study)","volume":"55","author":"Cady","year":"2015","journal-title":"Headache"},{"key":"10.1016\/j.ejpb.2017.11.001_b0535","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/jam.2004.17.249","article-title":"Bi-directional nasal delivery of aerosols can prevent lung deposition","volume":"17","author":"Djupesland","year":"2004","journal-title":"J. Aerosol Med.-Deposition Clearance Effects Lung"},{"key":"10.1016\/j.ejpb.2017.11.001_b0540","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/01.MLG.0000199741.08517.99","article-title":"Breath actuated device improves delivery to target sites beyond the nasal valve","volume":"116","author":"Djupesland","year":"2006","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ejpb.2017.11.001_b0545","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0167-5699(98)01307-3","article-title":"Immunology of the tonsils","volume":"19","author":"Perry","year":"1998","journal-title":"Immunol. Today"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641117307282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641117307282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T05:26:54Z","timestamp":1603258014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641117307282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":109,"alternative-id":["S0939641117307282"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2017.11.001","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal immunization with dry powder vaccines","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2017.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}